atidarsagene autotemcel Libmeldy
Selected indexed studies
- Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®). (Value Health, 2024) [PMID:38795960]
- A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD: What we have accomplished and what opportunities lie ahead. (JIMD Rep, 2023) [PMID:37701322]
- A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel. (Orphanet J Rare Dis, 2023) [PMID:37644601]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®). (2024) pubmed
- A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD: What we have accomplished and what opportunities lie ahead. (2023) pubmed
- A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel. (2023) pubmed
- Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy. (2022) pubmed